MASAMUNE Ken    Department   Research Institutes and Facilities, Research Institutes and Facilities    Position   Professor
Language	English
Title	First-in-human Clinical Trial of Sonodynamic Therapy with Drug Delivery System
Conference	5th COINS Symposium Shaping a dream! In-body hospitals -Future hearth care created by Kawasaki ventures-
Presentation Type	Poster notice
Publisher and common publisher	◎HORISE Yuki, OKAMOTO Jun, KONISHI Yoshiyuki, TAKEMAE,Kazuhisa Kazuhisa, KUSUDA Kaori, IZUMI Mikio , IKUTA Soko, MASAMUNE Ken, ISEKI Hiroshi, NISHIYAMA Nobuhiro , KATAOKA Kazunori, MURAGAKI Yoshihiro
Date	2018/12/14
Venue (city and name of the country)	Kawasaki
Society abstract	5th COINS Symposium 47
Summary	Sonodynamic therapy (SDT) uses a chemical sonosensitizer in combination with high- intensity focused ultrasound (HIFU), and it would reduce the reduction of drug dose and HIFU irradiation power compared to those of conventional monotherapies. From our previous study of four pet dogs with spontaneous tumors including osteosarcoma, hepatocellular cancer, and prostate cancer, the usefulness of SDT using an anticancer micelle (NC-6300) was confirmed. Based on the results, a clinical study involving the application of SDT method in humans was recently conducted at Tokyo Medical University. SDT method was used to treat human patients with unresectable, intractable cancers, such as pancreatic and biliary tract cancer, to evaluate its safety under set fixed conditions, including the dosage of NC-6300 and the output power of HIFU irradiation. While continuing a research into clarifying the action mechanism of this SDT approach such as radical oxygen, we plan to conduct an investigator-initiated clinical trial to evaluate the efficacy of SDT. This therapy has the potential to become a standard therapy and contribute to the treatment of both pet and human cancers.